Clinic of Internal Medicine IV, University Hospital Jena, Erlanger Allee 101, 07740 Jena, Germany.
Institute of Pharmacy, Department of Pharmaceutical Technology, Friedrich-Schiller University Jena, Otto-Schott-Strasse 41, 07745 Jena, Germany.
Adv Drug Deliv Rev. 2014 May;71:58-76. doi: 10.1016/j.addr.2013.10.001. Epub 2013 Oct 22.
Inflammatory bowel disease (IBD) is a frequently occurring disease in young people, which is characterized by a chronic inflammation of the gastrointestinal tract. The therapy of IBD is dominated by the administration of anti-inflammatory and immunosuppressive drugs, which suppress the intestinal inflammatory burden and improve the disease-related symptoms. Established treatment strategies are characterized by a limited therapeutical efficacy and the occurrence of adverse drug reactions. Thus, the development of novel disease-targeted drug delivery strategies is intended for a more effective therapy and demonstrates the potential to address unmet medical needs. This review gives an overview about the established as well as future-oriented drug targeting strategies, including intestine targeting by conventional drug delivery systems (DDS), disease targeted drug delivery by synthetic DDS and disease targeted drug delivery by biological DDS. Furthermore, this review analyses the targeting mechanisms of the respective DDS and discusses the possible field of utilization in IBD.
炎症性肠病(IBD)是一种常见于年轻人的疾病,其特征是胃肠道的慢性炎症。IBD 的治疗主要采用抗炎和免疫抑制药物,以抑制肠道炎症负担并改善与疾病相关的症状。已确立的治疗策略的特点是治疗效果有限和发生不良反应。因此,开发新的针对疾病的药物输送策略旨在实现更有效的治疗,并显示出解决未满足的医疗需求的潜力。本文综述了已确立的和面向未来的药物靶向策略,包括传统药物输送系统(DDS)的肠道靶向、合成 DDS 的疾病靶向药物输送和生物 DDS 的疾病靶向药物输送。此外,本文还分析了各自 DDS 的靶向机制,并讨论了其在 IBD 中的可能应用领域。